Site-specific conjugation is reshaping how antibody-drug conjugates are engineered, replacing the structural heterogeneity of random conjugation with defined, homogeneous constructs. As multiple bioconjugation platforms advance toward clinical and commercial maturity, conjugation site selection has emerged as a primary determinant of ADC pharmacokinetics and therapeutic index.
Key Takeaways
- Random conjugation to lysine or cysteine residues produces heterogeneous drug-antibody ratio (DAR) mixtures, with high-DAR species driving off-target toxicity and low-DAR species underdosing — narrowing the therapeutic window.
- Multiple site-specific platforms have reached clinical or late-preclinical stages, including engineered cysteine/unnatural amino acid incorporation (THIOMAB, ARX788), microbial transglutaminase conjugation (Araris AraLinQ™), glycan remodeling (Lonza (Synaffix) GlycoConnect™, Shanghai Tangling GlycanLink), and Fc-binding peptide-directed lysine conjugation (AJICAP, ABtis AbClick).
- Clinical validation is emerging: IBI343, a GlycoConnect™-enabled CLDN18.2-targeting ADC, demonstrated an objective response rate exceeding 40% in pancreatic ductal adenocarcinoma in Phase I/II data presented at ASCO 2025.
- Homogeneous conjugates show improved serum stability and reduced payload deconjugation compared to conventionally conjugated ADCs, translating to more predictable exposure-response relationships and manageable safety profiles.
- Site-specific platforms are enabling next-generation designs, including dual-payload ADCs and extension into non-ADC modalities such as antibody-oligonucleotide conjugates (AOCs).
Redefining Therapeutic Window
Antibody-drug conjugates (ADCs) represent one of the most compelling convergence points in modern oncology — combining the precision targeting of monoclonal antibodies with the cell-killing potency of cytotoxic payloads. Over the past decade, the field has seen remarkable clinical validation, with more than 15 ADCs approved by major regulatory agencies worldwide—a number that rises to nearly 20 when including approvals by China’s NMPA —reflecting the increasingly global distribution of ADC innovation. Yet as the pipeline matures and competition intensifies, a fundamental question has moved to the forefront of ADC design: does it matter where the drug is attached to the antibody?
The answer, increasingly, is a resounding yes. The shift from conventional random conjugation toward site-specific conjugation technologies represents one of the most consequential structural evolutions in ADC development. It is not merely a manufacturing preference — it is a strategy that directly impacts pharmacokinetics, therapeutic index, and ultimately, patient outcomes.
The Problem with Randomness
Early-generation ADCs were built by chemically conjugating to accessible lysine or cysteine residues. This approach, while practical, introduces a fundamental limitation: heterogeneity. A monoclonal IgG1 antibody carries approximately 80 lysine residues or 8 reactive reduced cysteines, and conjugation to these sites produces a statistical mixture of ADC species with DARs ranging from 0 to 8 or higher. High-DAR species tend to be hydrophobic and rapidly cleared, contributing to off-target toxicity; low-DAR species are underpowered. The net effect is a narrowed therapeutic window. As comprehensively reviewed in ADC clinical development literature, DAR profile, conjugation site, and payload physicochemical properties are among the most critical determinants of both efficacy and tolerability in clinical settings.[1] In short: the heterogeneity problem is not a manufacturing inconvenience — it is a clinical liability.
The Rise of Site-Specific Technologies
- Engineered Cysteine and Unnatural Amino Acid Incorporation: The THIOMAB platform, pioneered by Genentech, introduced engineered cysteine residues at defined antibody positions, enabling highly controlled DAR2 or DAR4 conjugation without the heterogeneity of random approaches. Genetic code expansion goes further, incorporating unnatural amino acids — such as para-acetyl-phenylalanine (pAF) — that carry bioorthogonal reactive handles entirely absent from the natural proteome. ARX788, a HER2-targeting ADC in clinical development, exemplifies this strategy: its pAF-based conjugation delivers a homogeneous, highly stable product with superior pharmacokinetics and minimal payload deconjugation in non-human primates, distinguishing it from earlier-generation HER2 ADCs.[2] The tradeoff is upstream complexity: both approaches require cell line engineering and modified expression systems.
- Enzymatic Conjugation via Microbial Transglutaminase (mTGase): Microbial transglutaminase (mTGase) selectively modifies a single conserved glutamine — Gln295 — in the IgG Fc region via a transamidation reaction, requiring no antibody engineering and consistently delivering homogeneous DAR2 conjugates via a stable isopeptide bond.[3]Importantly, Gln295 is only accessible to mTGase after trimming of the adjacent N-glycan — a prerequisite step that has been streamlined in modern implementations. Araris Biotech (Basel) represents one of the most advanced embodiments of this strategy. Their AraLinQ™ platform pairs mTGase-mediated Q295 conjugation with a hydrophilic RKAA-peptide linker, generating finished ADCs in one step from native, off-the-shelf antibodies in as little as 48 hours. In a 2025 head-to-head study published in Molecular Cancer Therapeutics, an Araris anti-CD79b–MMAE ADC (DAR2) demonstrated a 4–6-fold wider therapeutic window versus polatuzumab vedotin (Polivy®), a 3-fold higher non-severely toxic dose, and no detectable payload loss over 14 days in human serum.[4] Araris has since licensed AraLinQ™ to Chugai Pharmaceutical and acquired Innate Pharma’s transglutaminase patent portfolio — signals that mTGase conjugation is transitioning toward mainstream adoption. Beyond cytotoxic ADCs, the same enzymatic platform has been adapted for antibody-oligonucleotide conjugates (AOCs), opening siRNA and antisense delivery modalities.[5]
- Glycan Remodeling and Chemoenzymatic Click Chemistry: Glycan remodeling exploits the conserved N-glycan at Asn297 in the antibody Fc as a conjugation anchor — requiring no antibody sequence engineering and applicable to any existing IgG. Two platforms define the current landscape.
- Synaffix GlycoConnect™ uses an engineered endoglycosidase fusion (EndoSH) to trim native N-glycans to core GlcNAc, followed by enzymatic transfer of 6-azidoGalNAc and metal-free BCN-based click chemistry — achieving 90–95% overall conversion and well-defined DAR2/DAR4 products. The process has been validated at >0.5 kg scale and underpins multiple clinical programs including MGC026 (B7-H3, exatecan, DAR4) and MGC028 (ADAM9, exatecan, DAR4), both showing favorable cynomolgus monkey toxicity profiles without the ocular toxicity associated with tubulin inhibitor payloads.[6][7] The clinical impact of GlycoConnect™ is perhaps best illustrated by IBI343, Innovent Biologics’ CLDN18.2-targeting ADC (exatecan, DAR4) developed in collaboration with Synaffix. In a Phase I/II study presented at ASCO 2025, IBI343 demonstrated an objective response rate exceeding 40% in heavily pretreated pancreatic ductal adenocarcinoma — a tumor type historically resistant to most systemic therapies — establishing one of the most compelling early-phase efficacy signals in the field. GlycoConnect™ has further been extended to DAR8 via branched BCN spacers, with xenograft efficacy surpassing trastuzumab deruxtecan,[8]underscoring the platform’s flexibility across DAR formats and payload classes.
- Shanghai Tangling Biotech (GlycanLink), founded in 2021 by Dr. Huang Wei of the Chinese Academy of Sciences, has developed GL-OligosacLink® and GL-DisacLink® — two-generation glycosite-specific platforms. In the GL-OligosacLinkTM platform, Endo-S and its mutant are applied to trim native antibody glycans and transfer functional oligosaccharide, enabling the preparation of ADC with DAR4. In the 2nd DisacLink® platform, the newly developed TL-ENGase allows the one-step synthesis of LacNAc-based ADC with glycan trimming and transferring simultaneously, which substantially lowers costs. Currently, via rational design of LacNAc linkers, it can obtain highly homogeneous ADCs with DAR values of 1, 2, 4, 8, and higher. Dr. Huang Wei and his group have also independently developed a thioester-based FcBP acyl transfer reagent for K248 conjugation, and demonstrated a one-pot dual-site strategy combining both platforms to generate homogeneous dual-payload ADCs with defined DARs in a single reaction.[9] GlycoConnect™ leads in clinical precedent and published manufacturing data; GlycanLink’s one-step approach offers process streamlining that is attractive for early-stage programs and CDMO partnerships.
Both glycan platforms share a key structural advantage: the Asn297 conjugation site is spatially distant from the Fab antigen-binding domain, minimizing interference with target engagement. The buried Fc-glycan location also partially shields the hydrophobicity of attached payloads — contributing to improved pharmacokinetics and reduced aggregation propensity compared to conventional lysine- or cysteine-conjugated ADCs. A practical consideration for both is that glycan remodeling removes the native Fc N-glycan, which can reduce FcγR-mediated effector functions — a trade-off that warrants evaluation depending on the therapeutic indication
- Fc-Binding Peptide-Mediated Proximal Lysine Conjugation: A newer approach exploits the Fc domain’s three-dimensional structure as a proximity-directing scaffold. Small synthetic peptides bind with high affinity to the Fc, positioning a reactive warhead adjacent to a specific lysine. The reaction proceeds site-selectively, with the Fc-binding peptide (FcBP) released as a traceless byproduct — delivering homogeneous ADCs without antibody engineering or glycan modification.
- AJICAP (Ajinomoto) uses FcIII-like and Z34C peptide scaffolds to direct conjugation selectively to Lys248 and Lys288. Second-generation AJICAP (2023) achieves homogeneous DAR2 across >20 antibody-payload combinations spanning IgG1, IgG2, and IgG4 in a one-pot reaction, with aggregation below 3% and an MTD exceeding 80 mg/kg versus ~10 mg/kg for conventional stochastic ADCs.[10]
- ABtis (AbClick) targets Lys248 via proximity-driven S-to-N acyl transfer chemistry. The latest AbClick Pro H (2025) employs an intrinsic O-acyl hydroxamate leaving group — enabling scavenger-free, traceless conjugation with broad payload compatibility, a meaningful CMC simplification that has supported IND-enabling studies.[11]
The FcBP strategy represents a compelling middle ground: the precision of enzymatic approaches without requiring cell line engineering, glycan modification, or specialized fermentation infrastructure.
What Homogeneity Delivers
The clinical and preclinical evidence consistently points to one overarching benefit: an expanded therapeutic index. When every molecule carries the same number of drugs at the same positions, pharmacokinetics become predictable. Clearance rates stabilize. Payload deconjugation in circulation is minimized. The concentration of free, systemically active drug — the primary driver of off-target toxicity — decreases. In preclinical studies of EO-1022, a glycan site-specific HER3 ADC (DAR4), the conjugate maintained a stable, homogeneous DAR throughout 14-day incubation in human serum, while a cysteine-conjugated counterpart and patritumab deruxtecan both showed greater than 50% DAR reduction over the same period.[12] This translates directly to more predictable exposure-response relationships and more manageable safety profiles — the difference between an ADC that can be dosed at therapeutically meaningful levels and one constrained by toxicity before reaching the tumor.
Looking Ahead
The momentum behind site-specific conjugation is unlikely to reverse. As the ADC pipeline grows more competitive and the bar for differentiation rises, homogeneous, well-characterized conjugates with predictable pharmacology will increasingly become the baseline expectation — not a premium feature.
Several frontier directions deserve attention. First, integrating site-specific platforms with dual-payload strategies is enabling a new generation of ADCs that combine two mechanistically distinct cytotoxins on a single antibody, directly targeting tumor heterogeneity and drug resistance. Shanghai GlycanLink’s one-pot glycan plus K248 dual-site approach and ARARIS’s branched linker DAR4 format are early examples of how site-specific chemistry unlocks combinatorial design that is simply not achievable with random conjugation. Second, the extension of mTGase and glycan remodeling platforms to non-ADC modalities — including immune cell engagers, antibody-cytokine conjugates, and AOCs — signals that site-specific bioconjugation is becoming foundational infrastructure for the broader antibody therapeutics field.
Finally, as regulatory agencies accumulate experience with homogeneous ADCs in IND and BLA submissions, the expectation of well-defined conjugate populations is likely to sharpen. Sponsors who invest in site-specific platforms now will be better positioned for regulatory success as that expectation matures.
The era of random conjugation is not over — legacy products and certain payload-linker combinations may continue to favor conventional approaches. But the direction of travel is clear. In ADC design, as in so many areas of medicine, precision matters. And when it comes to where a cytotoxic drug is attached to an antibody, where it goes is everything.
References
[1] López de Sá A, Díaz-Tejeiro C, Poyatos-Racionero E, Nieto-Jiménez C, Paniagua-Herranz L, Sanvicente A, Calvo E, Pérez-Segura P, Moreno V, Moris F, Ocana A. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned. J Hematol Oncol. 2023 Dec 12;16(1):118. doi: 10.1186/s13045-023-01519-0. PMID: 38087293; PMCID: PMC10717055. https://doi.org/10.1186/s13045-023-01519-0
[2] Ali K, et al. ACE-Breast-03: A phase 2 study of ARX788 in HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan. Cancer Research. 2024;84(9 Suppl):Abstract nr PO1-04-02. https://doi.org/10.1158/1538-7445.sabcs23-po1-04-02
[3] Sadiki A, et al. Site-Specific Conjugation of Native Antibody: Transglutaminase-Mediated Modification of a Conserved Glutamine. Bioconjugate Chemistry. 2024;35(3):313–322. https://doi.org/10.1021/acs.bioconjchem.4c00013
[4] Probst P, Attinger-Toller I, Bertrand R, Stark R, Santimaria R, Schlereth B, Grabulovski D, Spycher PR. Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. Mol Cancer Ther. 2025 Jun 4;24(6):803-815. doi: 10.1158/1535-7163.MCT-24-0983. PMID: 40177869; PMCID: PMC12134749. https://doi.org/10.1158/1535-7163.MCT-24-0741
[5] Huggins IJ, Medina CA, Springer AD, van den Berg A, Jadhav S, Cui X, Dowdy SF. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. Molecules. 2019 Sep 10;24(18):3287. doi: 10.3390/molecules24183287. PMID: 31509944; PMCID: PMC6767100. https://doi.org/10.3390/molecules24183287
[6] Scribner JA, et al. Preclinical development of MGC026, a glycan-linked, exatecan-based ADC targeting B7-H3. Cancer Research. 2024;84(6 Suppl):Abstract nr 1904. https://doi.org/10.1158/1538-7445.am2024-1904
[7] Scribner JA, et al. Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based ADC. Cancer Research. 2024;84(6 Suppl):Abstract nr 1897. https://doi.org/10.1158/1538-7445.am2024-1897
[8] Lelieveldt L, et al. GlycoConnect™ ADC toolbox expansion with high DAR technology. Cancer Research. 2024;84(6 Suppl):Abstract nr 2614. https://doi.org/10.1158/1538-7445.am2024-2614
[9] Tang C, Zeng Y, Zhang J, Zheng X, Tang F, Yao X, Jiang ZX, Shi W, Huang W. One-Pot Assembly of Dual-Site-Specific Antibody-Drug Conjugates via Glycan Remodeling and Affinity-Directed Traceless Conjugation. Bioconjug Chem. 2023 Apr 6. doi: 10.1021/acs.bioconjchem.3c00048. Epub ahead of print. PMID: 37022330. https://doi.org/10.1021/acs.bioconjchem.3c00048
[10] Fujii T, et al. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production. Bioconjugate Chemistry. 2023;34(4):728–738. https://doi.org/10.1021/acs.bioconjchem.3c00040
[11] Son J, Seo JW, Park SH, Yeom H, Ko N, Lee YG, Kim J, Kim JH, Park SH, Han T, Chung SJ. AbClick Pro H: Scavenger-Free, Traceless Lys248 Conjugation Via O-Acyl Hydroxamate Chemistry for Homogeneous Antibody-Drug Conjugates (ADCs). Org Lett. 2026 Jan 16;28(2):764-767. doi: 10.1021/acs.orglett.5c04902. Epub 2025 Dec 31. PMID: 41474644. https://doi.org/10.1021/acs.orglett.5c04902
[12] O’Hare T, et al. Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC. Cancer Research. 2025;85(8 Suppl 2):Abstract nr LB004. https://doi.org/10.1158/1538-7445.am2025-lb004
Featured image: © 2026 Cha ADC JADC. Used with permission.
DOI
